study. The first is our speakers from Abbott Laboratories who will go over a very interesting study that they did on baseline correction and some other issues. It's an extremely interesting study. Steve Johnson will then speak for the FDA about our experience with levothyroxine bioavailability in quite a few NDAs that we've reviewed now.
The second case study is on potassium chloride and more detail will be gone into on our experience with potassium chloride, and finally I'll come back and just kind of wrap things up with a summary.
First off, Steve will introduce the topic of levothyroxine.
DR. JOHNSON: Good afternoon, ladies and gentlemen, members of the advisory committee. My name is Steven Johnson, and I'm a clinical pharmacology and biopharmaceutics reviewer, collocated with the Division of Metabolic and Endocrine Drug Products.
Today I'll be presenting on a very important endogenous drug substance that you've heard a lot about this morning, and this product has come to a focal point here at the Food and Drug Administration within the last